SAN DIEGO, CA – March 10, 2020 – Today, AnaBios announced a collaboration with Eli Lilly and Company (Lilly) to develop proprietary electrophysiology assays for preclinical drug discovery research. The collaboration will leverage AnaBios’ expertise in the recovery and interrogation of human cell and tissue samples.

The project will focus on ethically-consented samples of human spinal cord and provide an unprecedented preclinical paradigm for studying how new drug candidates can modulate the transmission of sensory and motor information between the brain and peripheral tissues.

“AnaBios is excited to work with Lilly to develop these new human central nervous system (CNS) based electrophysiology assays,” said Dr. Andre Ghetti, AnaBios’ Chief Executive Officer. “AnaBios routinely performs physiology and pharmacology studies with human dorsal root ganglion (DRG) neurons isolated with proprietary methods that fully preserve cellular functionality. We will employ the experience we’ve accumulated from the last 10 years of research with human neurons to develop highly translational assays based on CNS neurons.”

AnaBios will work  with Lilly neuroscientists to deliver specific assay endpoints and biomarkers of relevance to CNS drug development transitional questions. Once validated, the assays will become part of AnaBios’ unique translational research platform. Programs that could benefit from the new spinal cord assays include those focused on chronic pain, amyotrophic lateral sclerosis and other CNS diseases.

About AnaBios

Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies. AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease, pain and itch. In addition to working with Fortune 500 biotech companies, CROs and academia, AnaBios drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry. For more information about AnaBios, visit